Thera-SAbDab

BRONTICTUZUMAB

>   Structural Summary
TherapeuticBrontictuzumab
TargetNOTCH1
Heavy ChainQVQLVQSGAEVKKPGASVKISCKVSGYTLRGYWIEWVRQAPGKGLEWIGQILPGTGRTNYNEKFKGRVTMTADTSTDTAYMELSSLRSEDTAVYYCARFDGNYGYYAMDYWGQGTTVTVSS
Light ChainQAVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWFQQKPGQAPRTLIGGTNNRAPGVPARFSGSLLGGKAALTLSGAQPEDEAEYYCALWYSNHWVFGGGTKLTVL
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG2
Highest Clinical Trial (June '19)Phase-I
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed2014
INN Year Recommended2015
Companies InvolvedOncoMed Pharmaceuticals, University of Texas M. D. Anderson Cancer Center
Conditions Approvedna
Conditions ActiveColorectal cancer
Conditions DiscontinuedAdenoid cystic carcinoma, Solid tumours, Haematological malignancies
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]